REVIEW

Natural Products for Cancer-Targeted Therapy: Citrus Flavonoids as Potent Chemopreventive Agents

Edy Meiyanto*, Adam Hermawan, Anindyajati

Abstract

Targeted therapy has been a very promising strategy of drug development research. Many molecular mechanisms of diseases have been known to be regulated by abundance of proteins, such as receptors and hormones. Chemoprevention for treatment and prevention of diseases are continuously developed. Pre-clinical and clinical studies in chemoprevention field yielded many valuable data in preventing the onset of disease and suppressing the progress of their growth, making chemoprevention a challenging and a very rational strategy in future researches. Natural products being rich of flavonoids are those fruits belong to the genus citrus. Ethanolic extract of Citrus reticulata and Citrus aurantiifolia peels showed anticarcinogenic, antiproliferative, co-chemotherapeutic and estrogenic effects. Several examples of citrus flavonoids that are potential as chemotherapeutic agents are tangeretin, nobiletin, hesperetin, hesperidin, naringenin, and naringin. Those flavonoids have been shown to possess inhibition activity on certain cancer cells’ growth through various mechanisms. Moreover, citrus flavonoids also perform synergistic effect in combination with several chemotherapeutic agents against the growth of cancer cells. Some mechanisms involved in those activities are through cell cycle modulation, antiangiogenic effect, and apoptosis induction. Previous studies showed that tangeretin suppressed the growth of T47D breast cancer cells by inhibiting ERK phosphorylation. While in combination with tamoxifen, doxorubicin, and 5-FU, respectively, it was proven to be synergist on several cancer cells. Hesperidin and naringenin increased cytotoxicity of doxorubicin on MCF-7 cells and HeLa cells. Besides, citrus flavonoids also performed estrogenic effect in vivo. One example is hesperidin having the ability to decrease the concentration of serum and hepatic lipid and reduce osteoporosis of ovariectomized rats. Those studies showed the great potential of citrus fruits as natural product to be developed as not only the source of co-chemotherapeutic agents, but also phyto-estrogens. Therefore, further study needs to be conducted to explore the potential of citrus fruits in overcoming cancer

Keywords: Natural products - targeted therapy - cancer - citrus flavonoids - co-chemotherapy - chemoprevention

Introduction

Disease is the term commonly used to define a condition when impair of normal function occurs, both infectious and not. As a consequence of the dysfunction, in some cases, signs that are referred to medical symptoms appeared. Not only affecting and altering one’s life, these symptoms are also reducing quality of life, and moreover, might cause death. Globalization resulted certain impacts on people’s lifestyle, thus their health (Epperly et al., 2011). Exposure to UV rays and smoke cause various health disorders, such as hyperpigmentation, aging process, and increasing of skin and lung cancer risk (Elmets et al., 2010). Therefore, chemoprevention as an effort for treatment and prevention of diseases are continuously developed. As an examples are the use of antioxidants and anti-aging substances (Epperly et al., 2011).

Chemoprevention is defined as the use of substances of natural origin, biological agents, synthetic, or chemical compounds to prevent or suppress the disease progression, reverse to normal physiological functions and perform early detection of pathological conditions (Hirsch et al., 2002; Tsao et al., 2004). Chemopreventive agents, therefore, are expected to overcome several problems, such as skin cancer (melanoma), osteoporosis, and degenerative diseases (Lin & Tsai, 1999; Uliaasz & Spencer, 2004). Pre-clinical and clinical studies in this field has yielded many valuable data in preventing the onset of disease and suppressing the progress of their growth, making chemoprevention a challenging and a very rational strategy in future researches (Adhami et al., 2009; Bishahee et al., 2011).

Treatment of cancer, a disease with a complex molecular pathophysiology that varies according to each type, has been facing huge number of problems. Several ways in the treatment of breast cancer have been developed, that are surgery, chemotherapy, hormonal therapy, and radiation. The use of systemic chemotherapy does not show satisfying result, and even causes side
effects (Wattanapitayakul et al., 2005). The usage of doxorubicin, a chemotherapeutic agent commonly used in breast cancer treatment, showed low effectiveness, rendering to its resistance and toxicity on normal tissues (Fimognari et al., 2006). An approach in overcoming such problem is the development of agents used in combination with chemotherapeutic agents resulting in better result compared to chemotherapeutic agent alone (Fimognari et al., 2006). Therefore, study focusing on cancer chemoprevention has to be continuously conducted.

Another disease showing continuous increasing incidence are hypercholesterolemia and osteoporosis, particularly suffered by women entering their menopause phase. Those are a couple of common problems faced by women commonly linked to cancer development, because they are related to estrogen and estrogen receptor modulation (Yager & Davidson, 2006). Such hormones are being responsible in women’s physiological system, that are maintaining menstrual cycle, reproductive tissues, bone density, and also cholesterol modulation (Jordan, 2004). Estrogen deficiency may lead to disruption in reproductive tissues, increasing risk of cardiovascular dysfunction, hot flashes, and insomnia (Lewis-Wambi & Jordan, 2005). Since ER activation leads to the activation of replication machineries, people’s effort to overcome menopause and osteoporosis by using hormone replacement therapy brings along a higher risk of cancer, particularly breast and endometrial cancer (Yager & Davidson, 2006). Hormone replacement therapy is the use of exogenous estrogen in order to maintain certain normal functions in the body. The use of phytoestrogens as a replacement of estradiol being used in HRT to decrease cancer risk is then developed, thus categorized as chemopreventive agents (Shao & Brown, 2003). Not only phytoestrogens, compounds possessing antioxidant activity are also potential as chemopreventive agents (Seely et al., 2005).

As mentioned above, chemoprevention is one promising approach in overcoming cancer problems. Another main problems being faced in the application of chemotherapeutic agent are its toxicity towards normal tissues, suppression of the immune system, and occurrence of resistance (Mechtener et al., 1998; Wattanapitayakul et al., 2005). One promising approach to solve this problem is the application of cochemotherapeutic agent in cancer therapy (Brenner, 2002). Co-chemotherapy may increase chemotherapeutic agents’ efficacy, allowing the use of lower dosage of chemotherapeutic agent, resulting in the decrease of toxicity on normal tissues (Bastl et al., 2007). Increasing efficacy may be obtained by combining agents with established chemotherapeutic agents having additive or synergistic effect, while decreasing the toxicity may be achieved by the use of agents possessing immunomodulatory effect (Olson et al., 2007).

Citrus species is one example of natural product containing phytochemicals that is promising to be developed in cancer therapy. Numbers of studies have been conducted, providing information related to citrus’ potential as both chemopreventive and cochemotherapeutic agent. Here, we would like to explore citrus as a model of natural product to be developed for both preventing and overcoming cancer. Discussion would be focusing on two members of Citrus family, that are Citrus aurantiifolia and Citrus reticulata.

**Chemopreventive Properties of Citrus Flavonoids**

Cancer Chemoprevention Research Center (CCRC), Faculty of Pharmacy Universitas Gadjah Mada has explored several agents possessing biological activity related to cell growth and differentiation, either in the form of synthetic compounds or plant extracts. CCRC has explored at least two member of citrus family, e.g Citrus aurantiifolia and Citrus reticulata (Table I) and biological activities of their flavonoids, that are hesperidin, naringenin, naringin, nobiletin, and tangeretin (Table II). In combination with another studies conducted, those could be a very valuable information to be analyzed further as the source of information for future studies.

**Antioxidant Activity**

Antioxidants are agents possessing ability to interact with and stabilize free radicals, thus resulting in protection of cell damage. Since free radical DNA damage may cause cancer, antioxidants are then proposed to be able to slow and prevent further damage in the development of cancer. Though DNA oxidation and carcinogenesis have not been directly proven, studies gave indirect strong support of certain product of DNA oxidation acting as biomarker for assessing antioxidant status and cancer risk (Thompson, 2004).

Citrus peels has been known to be a potential natural antioxidants because of their phenolic and flavonoid compounds (Bocco et al., 1998; Li et al., 2006). C. aurantiifolia extract containing hesperidin as the most dominant flavonoid showed radical scavenging activity (Tumbas et al., 2010). Hesperidin was also proven to be moderately active as antioxidant detected by using electron spin resonance spectrophotometer (Al-Ashaal & El-Sheltawy, 2011). Hesperidin, nobiletin, and tangeretin showed antioxidant activity in various antioxidant assays in vitro (Yi et al., 2008).

**Suppression of Carcinogenesis**

Carcinogenesis is the process of initiation and promotion of cancer. The processes involved are complex, affected by genetics factors, environmental exposure, age, and others. For cancer cells to initiate and thrive, they have to be able to stimulate their growth, gather enough factors required, and avoid elimination mechanisms. Chemopreventive agents are compounds that are able to prevent, slow down, or stop carcinogenesis (Tamimi et al., 2005).

**In vivo** study showed that besides suppressing c-Myc expression, C. reticulata peels ethanolic extract with the dosage of 500 mg/kgBW might reduce the number of cells expressing N-Ras in DMBA-induced rats’ hepatic carcinogenesis (Putri et al., 2008; Nugroho et al., 2008) and its suppression of c-Myc expression as well. Nobiletin, flavonoid obtained from C. reticulata peels, blocked
Further study was then conducted via silico study on nobiletin and tangeretin, two flavonoids contained in *C. reticulata* peels (Johann et al., 2007). Those two citrus flavonoids do not bind c-Src (N-Ras' upstream) stronger that ATP and imatinib do, respectively, while imatinib-c-Src has more stable binding compared to that is on ATP-c-Src (Nugroho et al., 2008; Putri et al., 2008). Molecular docking of nobiletin and tangeretin on CYP1A2 (isoenzyme of chytochrome P-450 that is able to activate procarcinogenic substance, benzo[A]pyrene) showed that tangeretin binds CYP1A2 stronger than α-naphtoflavon, while nobiletin does not (Nugroho et al., 2010). Those *in silico* studies should be further conducted, in order to predict the mechanism of action of certain molecules, and also to be used as the basic information in the discovery of new active molecules for future researches.

While *C. aurantiifolia*, another member of citrus family, showed inhibition of mammary carcinogenesis of DMBA on female sprague sawley rats by apoptosis induction and inhibition of cell proliferation (Hastuti et al., 2008; Pratiwi et al., 2008). *Citrus aurantiifolia* peels contain some flavonoids such as naringin, hesperidin, naringenin, hesperitin, rutin, nobiletin, dan tangeretin (Choi et al., 2007). Twenty mg/kg BW hesperetin per oral daily administration for 15 weeks inhibit carcinogenesis on rat’s colon during and after initiation of 20 mg/kg BW 1,2 dimethylhydrazin (Aranganathan and Nalini, 2009).

**Effect on Cell Cycle Regulation**

Cancer is described as a disease produced by damage to cell cycle regulation. The presence of damage or mutations in the cells should stimulate cell death, but in cancer cells this phenomenon does not occur and the cell stays alive through the cell cycle with the accumulation of mutations in the cell. Characteristics of cancer cells one of which is the ability to grow without stimulation of growth due to changes in intracellular signaling pathways that cause cells to be able to enter the cell cycle with no need of positive or negative external stimuli (Foster, 2008).

Stimulation of growth began with the release of growth factors from the cell. Furthermore, these growth factors will bind to receptors on the cell membrane. Signals transmitted through the membrane into the cytoplasm and transcription factors resulted in the release of subsequent protein in the cell nucleus. It encourages cells to enter the cell cycle. Cells that will replicate undergo G1 phase (first gap phase) to S phase for DNA synthesis, S phase is followed by the G2 phase, where the cell prepares for duplicating equipments for M (mitosis) phase (Foster, 2008).

### Table 1. Chemopreventive effect of Citrus Ethanolic Extract

| Extract                          | Chemopreventive Effect | Biological Effect                                                                                           | Reference                  |
|----------------------------------|------------------------|-------------------------------------------------------------------------------------------------------------|----------------------------|
| Citrus reticulata peels (ethanolic) | Antioxidant            | Scavenge DPPH radicals and hydroxyl radicals, stabilizing sunflower oil during accelerated storage            | Tumbas et al., 2011        |
| Supression of carcinogenesis     |                        | Supress N-Ras and c-Myc expression in rats’ hepatic carcinogenesis                                         | Nugroho et al., 2008       |
|                                  |                        | Antiproliferative on rats’ mammary carcinogenesis with increase of p53 expression                           | Putri et al., 2008         |
| Apoptosis                        |                        | Antiproliferative on rats’ hepatic carcinogenesis by inducing apoptosis with increase of p53 expression     | Pratomo et al., 2008       |
| Angiogenesis and metastasis      |                        | Inhibiting new blood vessels formation and reduce number of macrophage cells on bFGF-induced chicken CAM’s embryo proliferative and increase VEGF expression on WiDr cells | Chrisnanto et al., 2008    |
|                                  |                        | Proliferative on MCF-7 cells                                                                               | Ardiani et al., 2008       |
|                                  |                        | Induce rats’ mammary gland development and increase uterus’ volume by increasing c-Myc expression; increase bone density and improve blood cholesterol profile | Puspita et al., 2008      |
| Estrogenic                       |                        | Proliferative on MCF-7 cells                                                                               | Yunas, et al., 2007        |
|                                  |                        | Induced doxorubicin on MCF-7 cells                                                                          | Supriyati et al., 2008     |
|                                  |                        | Inhibited proliferation of female sprague dawley rat mammary induced by DMBA by downregulation of c-myc     | Adelina et al., 2008b      |
|                                  |                        | Inhibited MCF-7 cells growth                                                                               | Ardiani et al., 2008       |
| Citrus aurantiifolia peels       | Supression of          | Inhibited proliferation of female sprague dawley rat mammary induced by DMBA by downregulation of c-myc     | Adina et al., 2008         |
|                                  | carcinogenesis         |                                                                                                             | Pratiwi et al., 2011       |
| Cell cycle regulation            |                        | Modulate MCF-7 cell cycle                                                                                 | CCRC, unpublished data     |
| Apoptosis                        |                        | Induced Apoptosis on female sprague dawley rat mammary induced by DMBA by upregulation of p53               | Hastuti et al., 2008       |
|                                  |                        | Increased apoptosis induction of doxorubicin by upregulation of p53 and down regulation of Bcl-2            | CCRC, unpublished data     |
| Co-chemotherapeutic              |                        | Increased cytotoxicity of doxorubicin on MCF-7 cells                                                      | Adina et al., 2008         |
### Table 2. Chemopreventive effect of Citrus Flavonoid on Molecular Targets

| Phytochemical and Chemical Structure | Chemopreventive Effect | Molecular Targets | Biological Effect | Ref. |
|-------------------------------------|------------------------|-------------------|-------------------|------|
| **Tangeretin**                      | Antioxidant            |                   | Scavenge DPPH radicals, hydroxyl radicals, superoxide anion radicals, hydrogen peroxides, and possess reducing power | Yi et al., 2008 |
| Supression of carcinogenesis        | c-Src CYP1A2           | Inhibit the activity (in silico study) | Nugroho et al., 2008; 2010; Putri et al., 2008 |
| Cell cycle regulation               | p53, p21, p37          | Upregulation on COLO 205 cells G1 arrest on MCF-7 cells | Pan et al., 2002; Morley et al., 2007 |
| Apoptosis                           | p53                    | Induce apoptosis on COLO 205 cells | Pan et al., 2002; Hirano et al., 1995 |
| Angiogenesis and metastasis         | ERK-2 HIF1-α           | Inhibit the activity (in silico study) | Puspita et al., 2008 |
| Estrogenic                          |                        |                   |                   | |
| Co-chemotherapeutic                 |                        | Increased cytotoxicity of doxorubicin on MCF-7 and T47D cells | Meiyanto et al., 2011 |
| **Nobiletin**                       | Antioxidant            | Scavenge DPPH radicals, hydroxyl radicals, superoxide anion radicals, hydrogen peroxides, and possess reducing power | Yi et al., 2008 |
| Supression of carcinogenesis        | c-Src CYP1A2           | Inhibit the activity (in silico study) | Nugroho et al., 2008; 2010; Putri et al., 2008 |
| Cell cycle regulation               |                        | Modulate cell cycle on TMK-1, MKN-45, MKN-74, KATO-III Induce G1 arrest on MDA-MB-435, MCF-7, HT-29 | Yoshimizu et al., 2004; Morley et al., 2007 |
| Apoptosis                           |                        | Induce apoptosis on TMK-1, MKN-45, MKN-74, KATO-III cells | Yoshimizu et al., 2004 |
| Angiogenesis and metastasis         | ERK-2 HIF1-α           | Inhibit the activity (in silico study) | Puspita et al., 2008 |
| Estrogenic                          |                        |                   |                   | |
| Co-chemotherapeutic                 |                        | Increased cytotoxicity of doxorubicin on MCF-7 and T47D cells | Meiyanto et al., 2011 |
| **Hesperidin**                      | Antioxidant            | Scavenge DPPH radicals, hydroxyl radicals, superoxide anion radicals, hydrogen peroxides, and possess reducing power | Al-Ashaal and El-Sheltawy, 2011 |
| Yi et al., 2008                      | ABC                    | ABC               | ABC               | |
| Supression of carcinogenesis        | PI3K                   | Inhibit the activity (in silico study) | Hastuti et al., 2008 |
| Cell cycle regulation               | CDK2                   | Inhibit the activity (in silico study) | Adina et al., 2008 |
| Apoptosis                           | p53                    | Upregulation on MCF-7 cells | CCRC, Unpublished data |
| Angiogenesis and metastasis         |                        |                   |                   | |
| Estrogenic                          |                        | Decrease serum and hepatic lipid concentration, reduce osteoporosis of ovariectomized rats | Chiba et al., 2003 |
| Co-chemotherapeutic                 | PgP                    | Inhibit the activity (in silico study) Increase cytotoxicity of doxorubicin on MCF-7 cells by modulating cell cycle and induce apoptosis | Adina et al., 2008; Hermawan et al., 2010; CCRC, unpublished data; Kusharyanti et al., 2011 |
|                                    | Bcl-2                  | Downregulation on HeLa cells | |
|                                    | Bax                    | Upregulation on HeLa cells | |
### Citrus Flavonoids as Potent Chemopreventive Agents

| Phytochemical and Chemical Structure | Chemopreventive Effect | Molecular Targets | Biological Effect | Ref. |
|-------------------------------------|------------------------|------------------|------------------|------|
| **Hesperetin**                      |                        |                  |                  |      |
|                                    | Antioxidant            | -                | -                |      |
|                                    | Supression of          | -                | -                |      |
|                                    | carcinogenesis         |                  |                  |      |
|                                    | Cell cycle regulation  | CDK2, CDK4,      | Downregulation on | Choi, 2007 |
|                                    |                        | Cyclin D         | MCF-7 Cells      |      |
|                                    | Apoptosis              | Caspase-3        | Activation on HL-60 cells | Chen et al., 2003 |
|                                    |                        |                  |                  |      |
|                                    | Angiogenesis and       | -                | -                |      |
|                                    | metastasis             |                  |                  |      |
|                                    | Estrogenic             | -                | -                |      |
|                                    | Co-chemotherapeutic     |                  |                  |      |
| **Nobiletin**                       |                        |                  |                  |      |
|                                    | Antioxidant            | -                | -                |      |
|                                    | Supression of          | -                | -                |      |
|                                    | carcinogenesis         |                  |                  |      |
|                                    | Cell cycle regulation  | -                | -                |      |
|                                    | Apoptosis              | Bcl-2, Bax       | Downregulation on HeLa cells; THP-1 cells | Park et al., 2008; Larasati et al., 2011 |
|                                    |                        |                  | Upregulation on HeLa cells; THP-1 cells |      |
|                                    | Angiogenesis and       | -                | -                |      |
|                                    | metastasis             |                  |                  |      |
|                                    | Estrogenic             | -                | -                |      |
|                                    | Co-chemotherapeutic     |                  |                  |      |
| **Naringin**                        |                        |                  |                  |      |
|                                    | Antioxidant            | LTC4             | Inhibit the transport | Leslie et al., 2001 |
|                                    | Supression of          | PI3K, PKC        | Inhibit the activity (in silico study) | Hastuti et al., 2008; Pratiwi et al., 2008 |
|                                    | carcinogenesis         |                  |                  |      |
|                                    | Cell cycle regulation  | p21, ATP         | Upregulation in 5637 bladder cancer cells inducing G1 arrest Bind on PI3K binding site | Kim et al., 2008; Hastuti et al., 2008 |
|                                    | Apoptosis              | CDK2             | Inhibit the activity (in silico study) | Adina et al., 2008 |
|                                    |                        |                  |                  |      |
|                                    | Angiogenesis and       | -                | -                |      |
|                                    | metastasis             |                  |                  |      |
|                                    | Estrogenic             | -                | -                |      |
|                                    | Co-chemotherapeutic     |                  |                  |      |

In an *in vitro* study, tangeretin alone induced G1 arrest by increasing the expression of CDK inhibitors p37 and p21 in COLO 205 human colon carcinoma cells (Pan et al., 2002). This compound has been proven to inhibit the growth of estradiol-stimulated T47D cells (Van Slambrouck et al., 2005). Inhibition of MCF-7 cell proliferation was observed after 4 days treatment and G1 phase arrest after 24, 48, and 72 hours treatment, respectively (Morley et al., 2007).

Nobiletin has been observed to be cytotoxic by modulating cell cycle on TMK-1, MKN-45, MKN-74, and KATO-III human gastric carcinoma cells (Yoshimizu et al., 2004). Another study showed that the compound induced G1 phase arrest on MDA-MB-435, MCF-7, and HT-29 cells (Morley et al., 2007).

Hesperetin shows anticancer activity on MCF-7 cells through cell accumulation at G1 phase by inhibiting the expression of CDK2, CDK4 and Cyclin D; increasing the expression of p21 and p27; and increasing the binding of CDK4 and p21, but not p27 or p57 (Choi, 2007). Whilst...
Naringenin inhibited MDA-MB-435 cells proliferation (Kanno et al., 2005) and showed antiestrogenic activity on ERα+ cells (Totta et al., 2004). Naringin, a glycoside form of naringenin, inhibited proliferation 5637 bladder cancer cells and induced G1 arrest by upregulation of p21 (Kim et al., 2008). Naringin also inhibited cell survival pathway by binding ATP on PI3K binding site (Hastuti et al., 2008).

Effect on Apoptosis

The balance between cell death and growth are important in the development and maintenance of body functions in multicellular organisms (Broker et al., 2005). The process of cell death also serves to repair damaged tissue and release cells that may be harmful (Hanahan and Weinberg, 2011). Disturbances in the balance between death and cell growth can cause pathological disorders such as disturbances in embryogenesis, degenerative neurological disease, and cancer development. Therefore, the balance between cell death and growth are strictly controlled and the presence of interference can be eliminated through a process called programmed cell death (Broker et al., 2005).

Apoptosis, among others, characterized by cell shrinkage, bebbing its plasma membrane, chromatin condensation, formation of apoptotic bodies and DNA fragmentation (Ward et al., 2008). This process requires ATP and the synthesis of certain proteins without an accompanying inflammatory response (Ward et al., 2008). Apoptosis may occur through two main pathways of extrinsic and intrinsic pathways. Extrinsic pathway involves activation of death receptors by ligand binding resulting in activation of caspase 8, whereas the intrinsic pathway occurs through mitochondrial pathway (Ward et al., 2008).

Tangeretin has been observed to have the lowest IC50 value on COLO 205 human colon carcinoma cells by triggering apoptosis and increasing p53 expression, compared with the other flavonoid compounds, such as apigenin, kaempferol, myricetin, quercetin, luteolin, nobiletin, and rutin (Pan et al., 2002). Tangeretin was also able to induce apoptosis on HL-60 human promyelocytic leukemia cells (Hirano et al., 1995). While nobiletin, another flavonoid obtained from C. reticulata peels, has been observed to be cytotoxic not only through modulating cell cycle, but also by inducing apoptosis on TMK-1, MKN-45, MKN-74, and KATO-III human gastric carcinoma cells (Yoshimizu et al., 2004).

Biological activities that have been observed in vitro were then followed by in vivo studies. Ethanolic extract of C. reticulata peels showed antiproliferative effect on rats’ mammary and liver carcinogenesis model in a dose dependent manner. The extract induced apoptosis on liver cells, but not on mammary cells, and increased p53 expressions on both tissues (Pratomo et al., 2008).

The concentration of 40 and 80 μM hesperetin shows cytotoxic activity and could activate caspase 3 on HL-60 cells stronger than hesperidin did. At the same concentration, hesperetin induces apoptosis on HL 60 cells, while hesperidin does not. Rutinoid group at C-7 causes the reduction of apoptotic induction on HL 60 cells by hesperidin (Chen et al., 2003). Naringenin induced apoptosis via p53 independent pathway on KATOIII and MKN-7 gastric cancer cells and HepG2, Hep3B and HuH7 liver cancer cells and also via intrinsic pathway by downregulation of Bcl2 and upregulation of Bax, caspase-3 activation and PARP cleavage on THP-1 leukemia cells (Kanno et al., 2005; Park et al., 2008).

Effect on Angiogenesis and Metastasis

Cancer cells can stimulate angiogenesis. Angiogenesis is the growth of new blood vessels around the cancer tissue to meet the needs of nutrients and oxygen to cells. If the requirements have been met with good cells, easily cancer cells can invade other tissues. Cancer cells have the ability to invade and spread throughout the body tissues. The ability of cancer cells to invade and spread to other tissues occurs through blood vessels and lymph vessels are called to the stage of metastasis (Hanahan & Weinberg, 2011).

C. reticulata extract possesses angiogenic activity by increasing VEGF expression on WiDr colorectal cancer cells (Puspita et al., 2008). In contrast, anti-angiogenic effect on bFGF-induced chicken CAM’s embryo by inhibiting new blood vessels formation both macroscopically and microscopically, and also reducing the number of macrophage cells were observed (Chrisnanto et al., 2008).

Several in silico studies have been conducted to observe tangeretin and nobiletin’s binding on certain proteins. To predict their mechanism of action in inducing angiogenesis, tangeretin and nobiletin are docked to the proteins ERK-2 and HIF1-α, respectively. Both molecules does not bind ERK-2 and HIF1-α as strong as ATP does. Despite of those data, in vivo study showed that still, those phytochemicals are potential to be developed as therapeutic agent for heart revascularization and placenta formation in pregnancy (Puspita et al., 2008).

Estrogenic Effects of Citrus Flavonoids

Estrogen plays an important role in the development and differentiation of breast and endometrial cells, thus may have certain effects in the growth of cancer (Glaeser et al., 2006). However, estrogen also plays an important role in maintaining bone density, cholesterol level, and reproductive tissues (Jordan, 2004). Those effects are mediated by specific receptor, that is estrogen receptor (ER). The binding of estrogens to ER plays an important role in the occurrence of estrogenic effect (Rollerova & Urbancikova, 2000). The binding triggers or inhibits the transcription of certain genes being responsive to estrogens. Besides, estrogen-ER complex may interact with transcription factors, such as SP-1 (Meyer et al., 2006). So, ER targeting could be an approach of both chemoprevention and cancer targeted therapy (Manni et al., 2011). Compounds possessing similar effect to estrogen is called to have estrogenic effect, and numerous biocompounds have been shown to be active as phytoestrogens.

Interactions of estrogen and ER affect the expression of HDL and LDL receptors, resulting in the increasing
of HDL and decreasing of LDL level, thus play a role in cholesterol modulation (Meyer et al., 2006), whilst estrogen’s role in maintaining bone density occurs through its ability to increase the activity of osteoblast and suppress the activity of osteoclast. The binding of estrogen to ER also may activate certain transcription factors, such as c-Myc, that later transcripts genes resulting in the activation of cell cycle.

_Citrus reticulata_ ethanolic extract was potential to be developed as phytoestrogen. The extract shows proliferative effect on WiDr cells in low concentrations, not by affecting COX-2 expression (Ardiani et al., 2008). Forty-eight-hours single treatment of _C. reticulata_ ethanolic extract on MCF-7 cells tend to show proliferative effect in a dose dependent manner, while combination with doxorubicin might suppress its proliferative effect (Yunas et al., 2007).

_C. reticulata_ peels ethanolic extract with the dosage of 500 mg/kgBW and 1000 mg/kgBW could induce rats’ mammary gland development by increasing c-Myc expression (Supriyati et al., 2008). The extract could increase uterus’ volume of Sprague-Dawley rats by increasing c-Myc expression (Adelina et al., 2008a). Besides, _C. reticulata_ peels extract increased bone density and improved blood cholesterol profile in dose dependent manner (Adelina et al., 2008b), whilst hesperidin decreased concentration of serum and hepatic lipid and reduced osteoporosis of ovariectomized rats (Chiba et al., 2003).

_Citrus Flavonoids as Potential Cancer Co-Chemotherapeutic Agents_

The phenomenon of resistance of breast cancer cells will decrease the efficacy of chemotherapeutic agents, so that research on breast cancer is directed at the development of the companion agent in combination chemotherapy. Combination with a chemopreventive agent can be an alternative option to overcome the problem of resistance of cancer cells and increase the effectiveness of chemotherapeutic agents (Fimognari et al., 2006). The combination is expected to be able to reduce drug toxicity to normal tissue, making it more effective in fighting cancer cells (Sharma et al., 2004; Tyagi et al., 2004).

Ethanolic extract of _Citrus aurantiifolia_ peels inhibited MCF-7 cells growth (IC50 59 g/ml) and increased the sensitivity of MCF-7 breast cancer cells against doxorubicin (Adina et al., 2008) by apoptosis induction and cell cycle modulation (CCRC, unpublished data). Hesperidin, a flavonoid in _C. aurantiifolia_ has been studied in combination with doxorubicin to increased cytotoxic effect in concentration of 200 nM doxorubicin and 100 μM hesperidin (Hermawan et al., 2010), modulated cell cycle and induced apoptosis of MCF-7 cells (CCRC, unpublished data). Hesperetin, aglycone of hesperidin, showed stronger cytotoxic activity than hesperidin because its’ less polarity makes it easier to penetrate the cell membrane (Chen et al., 2003).

In combination, tangeretin synergistically increases the cytotoxic effect of doxorubicin by inducing cells’ death and arresting cell cycle’s phase on MCF-7 and T47D breast cancer cells (Meiyanto et al., 2011*). Observation showed that nobiletin increased doxorubicin’s cytotoxic activity on MCF-7 cells, but not on T47D cells (Meiyanto et al., 2011*).

Previous study showed that hesperidin synergistically increased doxorubicin cytotoxic activity on HeLa cells by downregulation of Bcl-2 and upregulation of Bax (Kusharyanti et al., 2011). Hesperetin is a molecule having similar structure with Pgp inhibitor. Thus, the compound is expected to inhibit Pgp overexpression and could overcome the resistance problem. Based on these researches, the potential of hesperetin as an anticancer agent or combinational agent in reducing the resistance of cancer cells with specific target has to be revealed.

Naringenin decreased efflux of daunomycin on MCF-7/ADR cells by inhibition of Pgp (Chung et al., 2005). Naringenin also increased accumulation of mitoxantrone on MCF-7 cells and NCI-H460 lung cancer cells by inhibition of breast cancer resistance protein (BCRP) (Zhang et al., 2004). Naringenin also increased cytotoxicity of doxorubicin on MCF-7 cells and T47D cells (Fitriasari et al., 2010; Junedi et al., 2010) via apoptosis induction. Previous study showed that naringenin synergistically increased doxorubicin cytotoxic activity on HeLa cells by downregulation of Bcl-2 and upregulation of Bax (Larasati et al., 2011). Those data shows that citrus flavonoids are promising to be developed as co-chemotherapeutic agent in cancer therapy.

_Citrus as a Model of Prospective Natural Product in Cancer Chemoprevention and Cochemotherapy_

Cancer Chemoprevention Research Center (CCRC), Faculty of Pharmacy Universitas Gadjah Mada has explored several agents possessing biological activity related to cell growth and differentiation, either in the form of synthetic compounds or plant extracts. In this paper, at least two members of citrus family e.g _Citrus aurantiifolia_ and _Citrus reticulata_ has been discussed. Those could be a very valuable information to be analyzed further as the source of information for future studies regarding to the treatment and prevention of cancer. Besides, further and comprehensive studies on targeted therapy let us conduct a molecular approach in finding the scientific basis of natural products application (as traditional medicine) both solely and in combination with existing established drug, clinically.

References

Adelina R, Supriyati MD, Nawangsari DA, Ikawati M, Meiyanto E, (2008). Efek Estrogenik Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) dalam Peningkatan Bobot Uterus Tikus Terovarietomi, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 301-309 (In Indonesia).

Adelina R, Supriyati MD, Nawangsari DA, Jenie RI, Meiyanto E, (2008*). Citrus reticulata Peels Modulate Blood Cholesterol Profile and Increased Bone Density of Ovariectomized Rats. _Indonesian J Biotechnology_, **12**, 1092-7.
Clayton AJ, Danson S, Jolly S, et al (2004). Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer, Br J Cancer, 91, 639-43.

Cragg GM, Newman DJ (2005). Plants as a source of anti-cancer agents, J Ethnopharmacology, 100, 72-9.

Dai Y, Liu M, Tang W, et al (2008). Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis, Clin Cancer Res, 14, 7701-10.

Elmets CA, Viner JL, Pentland AP, et al (2010). Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-blind, Placebo-Controlled Trial, J National Cancer Institute, 102, 2315-44.

Epperly MW, Wang H, Jones JA, et al (2011). Antioxidant-Chemoprevention Diet Ameliorates Late Effects of Total-Body Irradiation and Supplements Radioprotection by MnSOD-Plasmid Liposome Administration, Radiat Res, 175, 759-65.

Fimognari C, Nusse MN, Lenzi M, et al (2006). Sulfophanore Increases The Efficacy of Doxorubicin in Mouse Fibroblasts Characterized by p53 Mutations, Mutation Research, 601, 92-101.

Fitrissari A, Susidarti RA, Meiyanto E (2010). Peningkatan Efek Sitotoksik Doxorubicin oleh Naringenin pada Sel Kanker Payudara MCF-7, J Bahan Alam Indonesia, 7, 165-70.

Fong WF, Wang C, Zhu GY, et al (2007). Reversal of Multidrug Resistance in Cancer Cells by Rhizoma Alismatis Extract, Phytochemistry, 14, 160-5.

Foster I (2008). Cancer: A cell cycle defect, Radiography, 14, 144-9.

Glaeser M, Niederacher D, Djahansouz S, et al (2006). Effects of the Antiestrogens Tamoxifen andRaloxifene on the Estrogen Receptor Transactivation Machinery, Anticancer Res, 26, 725-44.

Guo BH, Kail GY, Jin HB, Tang KX (2006). Taxol Synthesis, African J Biotechnology, 5, 15-20.

Hastuti N, Pratiwi D, Armandari I, et al (2008). Ekstrak Etanolik Kulit Buah Jeruk Mandarin (Citrus reticulata) Memacu Proliferasi dan Ekspresi Cox-2 pada Sel Kanker Kolon WiDr, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 193-198 (In Indonesia).

Basil A, Kaseirov H, Den Hartog GM, Haenen GRMM, Van Der Vigh WJF (2007). Protectors Against Doxorubicin-Induced Cardiotoxicity: Flavonoids, Cell Biol Toxicol, 23, 39-47.

Bishayee A., Ahmed S., Brankov N., Perloff M (2011). Triterpenoids as Potential Agents for The Chemoprevention and Therapy of Breast Cancer, Front Biosci, 1, 980-96.

Bocco A, Cuvelier ME, Richard H, Berset C (1998). Antioxidant Activity and Phenolic Composition of Citrus Peel and Seed Extracts, J Agric Food Chem, 46, 2123-9.

Brenner DE (2002). New Paradigms in Oncological Therapeutics: Redefining Combination Chemotherapy, Annals of Oncology, 13, 1697-8.

Broker L, Kruyt FAE, Giacccone G (2005). Cell Death Independent of Caspases: A Review, Clin Cancer Res, 11, 3155-62.

Carpenter (2004). The EGF Receptor Family, Biologic Mechanism and Role in Cancer, Elsevier Academic Press.

Chen Y, Shen S, Lin H (2003). Rutinoside at C7 Attenuates The Apoptosis-Inducing Activity of Flavonoids, Biochemical Pharmacology, 66, 1139-50.

Chiba H, Uehara M, Wu J, et al (2003). Hesperidin, a Citrus Flavone Characterized by p53 Mutations, Mutation Research, 575, 149-57.

Chung SY, Sung MK, Kim NH, et al (2005). Inhibition of P-Glycoprotein by Natural Products in Human Breast Cancer Cells, Arch Pharm Res, 28, 823-8.

Clayton AJ, Danson S, Jolly S, et al (2004). Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer, Br J Cancer, 91, 639-43.

Edy Meiyanto et al

Adhami VM, Khan N, Mukhtar H (2009). Cancer Chemoprevention by Pomegranate: Laboratory and Clinical Evidence, Nutr Cancer, 1, 811-5.

Adina AB, Handoko FF, Setyarini H, et al (2008). Ekstrak Etanolik Kulit Jeruk Nips (Citrus aurantiifolia (Cristm.) Swingle) Meningkatkan Sensitivitas Sel MCF-7 terhadap Doxorubicin, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 55-62, (In Indonesia).

Akao Y, Itoh T, Oguchi K, Iinuma M, Nozawa Y (2008). Interactive Effects of Polymethoxy Flavonoids from Citrus on Cell Growth Inhibition in Human Neuroblastoma SH-SY5Y cells, Bio & Med Chemistry, 16, 2803-10.

Al-Ashaal HA, El-Sheltawy ST (2011). Antioxidant Capacity of Hesperidin from Citrus Peel Using Electron Spin Resonance and Cytotoxic Activity against Human Carcinoma Cell Lines, Pharm Biol, 49, 276-82.

Aranganathan S, Nalini N (2009). Efficacy of The Potential Chemopreventive Agent, Hesperetine (Citrus flavanone), on 1,2-Dimethylhydrazine Induced Colon Carcinogenesis, Food Chem Toxicol, 47, 2594-600.

Aradiani M, Puspita N, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Ekstrak Etanolik Kulit Buah Jeruk Mandarin (Citrus Reticulata) Memacu Proliferasi dan Ekspresi Cox-2 pada Sel Kanker Kolon WiDr, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 193-198 (In Indonesia).

Basto A, Kaseirov H, Den Hartog GM, Haenen GRMM, Van Der Vigh WJF (2007). Protectors Against Doxorubicin-Induced Cardiotoxicity: Flavonoids, Cell Biol Toxicol, 23, 39-47.

Bishayee A., Ahmed S., Brankov N., Perloff M (2011). Triterpenoids as Potential Agents for The Chemoprevention and Therapy of Breast Cancer, Front Biosci, 1, 980-96.

Bocco A, Cuvelier ME, Richard H, Berset C (1998). Antioxidant Activity and Phenolic Composition of Citrus Peel and Seed Extracts, J Agric Food Chem, 46, 2123-9.

Brenner DE (2002). New Paradigms in Oncological Therapeutics: Redefining Combination Chemotherapy, Annals of Oncology, 13, 1697-8.

Broker L, Kruyt FAE, Giacccone G (2005). Cell Death Independent of Caspases: A Review, Clin Cancer Res, 11, 3155-62.

Carpenter (2004). The EGF Receptor Family, Biologic Mechanism and Role in Cancer, Elsevier Academic Press.

Chen Y, Shen S, Lin H (2003). Rutinoside at C7 Attenuates The Apoptosis-Inducing Activity of Flavonoids, Biochemical Pharmacology, 66, 1139-50.

Chiba H, Uehara M, Wu J, et al (2003). Hesperidin, a Citrus Flavonoid, Inhibits Bone Loss and Decreases Serum and Hepatic Lipids in Ovariectomized Mice, J Nutri, 133, 1892-7.

Choi S, Ko H, Ko S, et al (2007). Correlation between Flavonoid Content and the NO Production Inhibitory Activity of Peel Extracts from Various Citrus Fruits, Biol Pharm Bull, 30, 772-8.

Chong PK, Lee H, Zhou J, et al (2010). ITIH3 is a Potential Biomarker for Early Detection of Gastric Cancer, J Proteome Res, 9, 3671-9.

Christnanto E, Adelina R, Putri DPP, et al (2008). Antiangiogenic effect of ethanol extract of Citrus reticulata peel in the Allantoic Membrane (CAM) induced by bFGF, Proceeding, The International Symposium on Molecular Targeted Therapy, ISBN-978-979-95107-6-1, 57-66.

Chung SY, Sung MK, Kim NH, et al (2005). Inhibition of P-Glycoprotein by Natural Products in Human Breast Cancer Cells, Arch Pharm Res, 28, 823-8.

Clayton AJ, Danson S, Jolly S, et al (2004). Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer, Br J Cancer, 91, 639-43.

Cragg GM, Newman DJ (2005). Plants as a source of anti-cancer agents, J Ethnopharmacology, 100, 72-9.

Dai Y, Liu M, Tang W, et al (2008). Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis, Clin Cancer Res, 14, 7701-10.

Elmets CA, Viner JL, Pentland AP, et al (2010). Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-blind, Placebo-Controlled Trial, J National Cancer Institute, 102, 2315-44.
Junedi S, Susidarti RA, Meiyanto E (2010). Peningkatan Efek Sitotoksik Doxorubicin oleh Naringenin pada Sel Kanker Payudara T47D melalui Induksi Apoptosis, J Ilmu Farmasi Indonesia, 8, 85-90.

Kanno S, Tomizawa A, Hiura A, et al (2005). Inhibitory Effects of Naringenin on Tumor Growth in Human Cancer Cell Lines and Sarcoma S-180-Implanted Mice, Biol Pharm Bull, 28, 529-32.

Kiguchi K, Goharnejad S, Chan K, et al (2001). Constitutive Expression of ErbB-2 in Gastric Epithelial Cells in Development of Adenocarcinoma, Cancer Res, 61, 6971-4.

Kim D, Lee S, Park K, et al (2008). Requirement for Ras/Raf/ERK Pathway in Naringin-Induced G1-Cell Cycle Arrest Via p21WAF1 Expression, Carcin, 29, 1701-9.

Kim H, Moon JY, Mosaddik A, Cho SK (2010). Induction of Apoptosis in Human Cervical Carcinoma HeLa Cells by Polyphenol-flavone-Rich Citrus grandis Osbeck (Danguyuja) Leaf Extract, Food & Chemical Toxicology, 48, 2435-42.

Kusharyanti I, Larasati, Susidarti RA, Meiyanto E (2011). Naringenin Increases Cytotoxic Activity of Doxorubicin on Hela Cell Line Through Cell Cycle Modulation and Apoptosis Induction, Indonesian J Cancer Chemoprevention, 24, 207-77.

Larasati, Kusharyanti I, Susidarti RA, Meiyanto E (2011). Naringenin Enhances The Anti-Tumor Effect of Doxorubicin on Hela Cervical Cancer Cells Through Cytotoxic Activity and Apoptosis Induction, Indonesian J Cancer Chemoprevention, 2, In Press.

Lee KW, Bode AM, Dong Z (2011). Molecular Targets of Phytochemicals for Cancer Prevention, Nature Reviews Cancer, 11, 211-8.

Leslie EM, Mao Q, Olescuk CJ, Deely RGC, Susan PC (2002). Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1) Transport and ATPase Activities by Interaction with Dietary Flavonoids, Flavonoid Modulation of MRP1 Transport and ATPase Activities, 59, 1171-80.

Lewis-Wambi JS, Jordan VC (2005). Treatment of Postmenopausal Breast Cancer With Selective Estrogen Receptor Modulators (SERMs). Breast Dis, 24, 93-105.

Li BB, Smith B, Hossain MM (2006). Extraction of Phenolics from Citrus Peels. I. Solvent Extraction Method, Sep Purif Technol, 48, 182-8.

Lin JK, Tsai SH (1999). Chemoprevention of Cancer and Cardiovascular Disease by Resveratrol, Proc Natl Sci Coun Repub China B, 23, 99-106.

Manni A, Xu H, Washington S, et al (2011). The Effects of Tamoxifen and Fish Oil on Mammary Carcinogenesis in Polyma Middle T Transgenic Mice, Horm Cancer, DOI: 10.1007/s12282-011-0078-2.

Matheny CJM, Lamb MW, Brouwer KLR, Pollack GM (2001). Pharmacokinetic and Pharmacodynamic Implications of P-glycoprotein Modulation, Pharmacotherapy, 21, 778-96.

Mecdetner E, Kystsoobayeva A, Zonis S, et al (1998). Levels of Multidrug Resistance (MDR1) P-Glycoprotein Expression by Human Breast Cancer Correlate with in vitro Resistance to Taxol and Doxorubicin, Clin Cancer Res, 4, 389-98.

Meiyanto E, Fitriasari A, Hermawan A, Junedi S, Susidarti RA (2011). The Improvement of Doxorubicin Activity by Citrus Flavonoid Tangeretin through Cell Cycle Modulation and Apoptotic Induction on Breast Cancer Cell Lines, Oriental Pharmacy and Experimental Medicine, DOI 10.1007/s13596-011-0016-4.

Puspita N, Ardiani M, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Docking Molekuler pada Protein Target CYP1A2, Farmasains, 1, 37-44.

Payudara T47D melalui Induksi Apoptosis, Sitotoksik Doxorubicin oleh Naringenin pada Sel Kanker Payudara T47D melalui Induksi Apoptosis, J Ilmu Farmasi Indonesia, 8, 85-90.

Puspita N, Ardiani M, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Docking Molekuler pada Protein Target CYP1A2, Farmasains, 1, 37-44.

Nahta R, Hortobagy GN, Estevae FJ (2003). Growth factor receptors in breast cancer: potential for therapeutic intervention, Oncologist, 8, 5-17.

Nugroho PA, Putri DA, Darma AP, Riyanto S, Meiyanto E (2008). Penelusuran Mekanisme Penekanan Ekspresi N-Ras Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Docking Molekuler pada Protein Target C-SRC dan CYP1A2, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 184-192.

Nugroho PA, Sukamdi DP, Darma AP, Jenie RI, Meiyanto E (2008). Penelusuran Mekanisme Flavonoid Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Melalui Docking Molekuler pada Protein Target CYP1A2, Farmasains, 1, 37-44.

Ohsahi H, Asamoto M, Tujimura K, et al (2004). Inhibition of Cell Proliferation by Nobiletin, A Dietary Phytochemical, Associated With Apoptosis and Characteristic Gene Expression, But Lack Of Effect on Early Rat Hepatocarcinogenesis In Vivo, Cancer Sci, 95, 936-42.

Oliver S, Robe P, Bours V (2006). Can NFκB be a Target for Novel and Efficient Anti-cancer Agents?, Biochemical Pharmacology, 72, 1054-68.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Parwati DH, Plumb A, McMillan I, et al (2008). Comparison of the Antioxidant and Prooxidant Activities of Tangeretin in Rat Blood, Food Chem Toxicol, 46, 3684-90.

Pratwi D, Hadijati S, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Modulation of Fatty Acid Oxidation and Apoptosis Induction on Breast Cancer Cell Lines, Journal of Nutrition and Food Sciences, 23, 1677-84.

Park JH, Jun CY, Lee BK, et al (2008). Naringenin Induces Apoptosis Through Downregulation of Akt and Caspase-3 Activation in Human Leukemia THP-1 Cells, Food Chem Toxicol, 46, 3684-90.

Puspita N, Ardiani M, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Docking Molekuler pada Protein Target CYP1A2, Farmasains, 1, 37-44.

Pratwi D, Hadijati S, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Docking Molekuler pada Protein Target CYP1A2, Farmasains, 1, 37-44.

Pratwi D, Hadijati S, Gunadi FA, Septisetyani EP, Meiyanto E (2008). Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) Sebagai Agen Kemopreventif Docking Molekuler pada Protein Target CYP1A2, Farmasains, 1, 37-44.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.

Pan MH, Chen WJ, Shiau SYL, Ho CT, Lin JK (2002). Tangeretin Induced Cell Cycle G1 Arrest through Inhibiting Cyclin-Dependent Kinases 2 and 4 As Well as Inhibiting Cyclin E, Cell Cycle, 4, 1463-1471.
436  Asian Pacific Journal of Cancer Prevention, Vol 13, 2012

Stereospecific Disposition and Anti-Cancer Activity of the Chiral Bioflavonoids Hesperetine and Hesperidine in Rodents, Humans, and Fruit Juices, Canadian Society of Pharmaceutical Sciences Annual Meeting, Vancouver, British Columbia, J Pharmacy, 7, 76.

Yang JY, Ha S, Yang Y, Kim JW (2010). p-Glycoprotein ABCB5 and YB-1 Expression Plays a Role In Increased Heterogeneity of Breast Cancer Cells: Correlations with Cell Fusion and Doxorubicin Resistance. BMC Cancer, 10, 1-10.

Yi Z, Yu Y, Liang Y, Zeng B (2008). In vitro antioxidant and antimicrobial activities of the extract of Pericarpium Citri Reticulatae of a new Citrus cultivar and its main flavonoids, Food Sci Tech, 41, 597-603.

Yoshimizu N, Otani Y, et al. (2004). Anti-tumour Effects of Nobiletin, A Citrus Flavonoid, on Gastric Cancer Include: Antiproliferative Effects, Induction of Apoptosis and Cell Cycle Deregulation, Aliment Pharmacol Ther, 1, 95-101.

Yunas SR, Latifah N, Rokhman MR, Fitriasari A, Meiyanto E (2007). Penggunaan Ekstrak Etanolik Kulit Buah Jeruk Mandarin (Citrus reticulata) Untuk Meningkatkan Sensitivitas Sel Kanker Payudara MCF-7 Terhadap Agen Kemoterapi Doxorubincin, PHARMACON, 8, 64-69.

Zhou W, Ercan D, Chen L, et al (2009). Novel Mutant-Selective EGFR Kinase Inhibitors against EGFR T790M, Nature, 24, 1070-4.

Edy Meiyanto et al

reticulata) Meningkatkan Ekspresi Faktor Angiogenik VEGF pada Sel Kanker Kolon WiDr, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 50-54 (In Indonesia).

Putri DA, Nugroho PA, Darma AP, et al. (2008). Potensi Kemopreventif Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata) pada Sel Kanker Hepar Tikus Galur Sprague Dawley Terinduksi 7, 12-Dimetilbenzen[A]antrasena Melalui Penekanan Ekspresi c-Myc, Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 75-80 (In Indonesia).

Robinson TP, Ehlers T, Hubbard IV, et al (2003). Design, Synthesis, and Biological Evaluation of Angiogenesis Inhibitors: Aromatic Enone and Dienone Analogues of Curcumin, Bioorg Med Chem Lett, 13, 11-7.

Rollerova E, dan Urbancikova M (2000). Intracellular Estrogen Receptors, Their Characterization and Function (Review), Endocrine regulations, 34, 203-18.

Seely D, Mills EJ, Wu Ping, Verma S, Guyatt GH (2005). The Effects of Green Tea Consumption on Incidence of Breast Cancer and Recurrence of Breast Cancer: A Systematic Review and Meta-analysis, Integrative Cancer Therapies, 4, 144-55.

Shao W, Brown M (2003). Advances in Estrogen Receptor Biology: Prospects for Improvements in Targeted Breast Cancer Therapy, Breast Cancer Research, 6, 39-52.

Sharma G, Tyagi AK, Singh RP, Chan DCF, Agarwal R (2004) Synergistic Anti-Cancer Effect of Grape Seed Extract and Conventional Cytotoxic Agent Doxorubicin Against Human Breast Carcinoma Cells, Breast Cancer Res & Treatment, 85, 1-12.

Supriyati MD, Adelina R, Nawangswari DA, Ikawati M, Meiyanto E (2008). Modulasi Ekspresi c-Myc Sel Epitelial Kelenjar payudara Tikus oleh Ekstrak Etanolik Kulit Jeruk Keprok (Citrus reticulata), Proceeding, Kongres Ilmiah XVI Ikatan Sarjana Farmasi Indonesia, 70-74. (In Indonesia).

Tamimi RM, Lagiou P, Adami H, Trichopoulo D (2002). Prospect for Chemoprevention of Cancer, Canc Contr J, 4, 55-64.

Thompson HJ (2004). DNA Oxidation Products, Antioxidant Status, and Cancer Prevention, J Nutr, 134, 3186-7.

Tota P, Acconcia F, Leone S, Cardillo I, Marino M (2004). Mechanisms of Naringenin-Induced Apoptotic Cascade in Cancer Cells: Involvement of Estrogen Receptor Alpha and Beta Signalling, JUBMB Life, 56, 491-9.

Tsao AS, Kim ES, Hong WK (2004). Chemoprevention of Cancer, CA Cancer J Clin, 54, 150-80.

Tumbas VT, Cetkovic GS, Djilas SM, et al. (2010). Antioxidant Activity of Mandarin (Citrus reticulata) peel, Apteef, 41, 195-203.

Tyagi AK, Agarwal C, Chan DCF, Agarwal R (2004). Synergistic Anti-Cancer Effects of Silibinin with Conventional Cytotoxic Agents Doxorubicin, cisplatin and Carboplatin against Human Breast Carcinoma MCF-7 and MDA-MB-468 Cells. Oncology Reports, 11, 493-9.

Ulissi A, Spencer JM (2004). Chemoprevention of Skin Cancer and Photoaging, Clinics in Dermatology, 22, 178-82.

Van Slambrouck S, Parmar VS, Sharma SK, et al (2005). Tangeretin Inhibits Extracellular-signal-Regulated Kinase (ERK) Phosphorylation, FEBS Lett, 579, 1665-9.

Vora T, De azambuja E, Awada A, Piccart M (2009). Novel Therapeutics in Breast Cancer-Looking to The Future, Update on Cancer Therapeutics, 3, 189-205.

Watthanapatayakul SK, Chularojmontri L, Herunsalee A, et al (2005). Screening of Antioxidants from Medicinal Plants for Cardioprotective Effect against Doxorubicin Toxicity, Basic and Clin. Pharmacol & Toxicol, 96, 80-7.

Yager JD, Davidson NE (2006). Estrogen Carcinogenesis in Breast Cancer, N Engl J Med, 354, 270-82.

Yanez JA, Roupe KA, Fukuda C, Teng XW, Davies NM (2004)